SpectraCure is focused on cancer treatment utilizing laser light sources and a photosensitizing drug, so called interstitial photodynamic therapy (PDT). This treatment modality is suitable for solid cancer tumors, for example in the prostate, pancreas as well as ear, nose and throat. SpectraCure has chosen recurrent prostate cancer treatment as the first market indication.
The SpectraCure technology is based on over 30 years of scientific research and work with interstitial PDT in combination with clinical experience from more than 3 000 photodynamic treatments of superficial lesions.
The proprietary SpectraCure interstitial PDT system relies on administration of a photosensitizing drug, and non-thermal laser light under management of a unique new dosimetry approach. SpectraCure has developed and patented the software IDOSE® for safe, accurate and efficient interstitial PDT treatment of solid cancer tumors.
The SpectraCure system offers significant potential clinical benefits for treating tumors that are otherwise inaccessible by illumination from outside of the body. The procedure is minimally invasive, and the system allows clinicians to individually adjust the treatment parameters with high accuracy for each cancer patient and tumor. This optimizes the efficacy of the treatment and minimizes unwanted side effects.